TY - JOUR
T1 - Primary Sarcomatoid Carcinoma of the Lung
T2 - Radiometabolic (18F-FDG PET/CT) Findings and Correlation with Clinico-Pathological and Survival Results
AU - Rapicetta, Cristian
AU - Lococo, Filippo
AU - Stefani, Alessandro
AU - Rossi, Giulio
AU - Ricchetti, Tommaso
AU - Filice, Angelina
AU - Franceschetto, Antonella
AU - Treglia, Giorgio
AU - Paci, Massimiliano
PY - 2016/8/1
Y1 - 2016/8/1
N2 - Introduction: Pulmonary sarcomatoid carcinoma (PSC) is a very rare and uninvestigated subtype of non-small cell lung cancer (NSCLC). Methods: The aims of this study were to define the radiometabolic features (by 18F-FDG PET/CT) in a bi-centric cohort of 49 PSC patients and to explore their relation with clinico-pathological characteristics and long-term survival results after surgical treatment. Results: There were 40 males and 9 females aged 65.2 ± 10.47 years. Overall long-term survival was 26.7 % at 5 years. Mean and median values of SUVmax were 15.21 and 15, respectively (SD ±5.5). Performing an age-, gender- and staging-matched analysis comparing PSC Stage-I only with a cohort of Stage-I NSCLC (n = 93), we observed significantly higher SUVmax values in PSC group (15.11 vs 7.66, p = 0.001). Conclusions: No differences in terms of SUVmax were found with regard to tumour dimensions, histology (pure vs mixed, pleomorphic vs others), pathological stage and pattern of recurrence. P-stage, surgical radicality, vascular/lymphatic invasion but not SUVmax affected long-term survival in PSC.
AB - Introduction: Pulmonary sarcomatoid carcinoma (PSC) is a very rare and uninvestigated subtype of non-small cell lung cancer (NSCLC). Methods: The aims of this study were to define the radiometabolic features (by 18F-FDG PET/CT) in a bi-centric cohort of 49 PSC patients and to explore their relation with clinico-pathological characteristics and long-term survival results after surgical treatment. Results: There were 40 males and 9 females aged 65.2 ± 10.47 years. Overall long-term survival was 26.7 % at 5 years. Mean and median values of SUVmax were 15.21 and 15, respectively (SD ±5.5). Performing an age-, gender- and staging-matched analysis comparing PSC Stage-I only with a cohort of Stage-I NSCLC (n = 93), we observed significantly higher SUVmax values in PSC group (15.11 vs 7.66, p = 0.001). Conclusions: No differences in terms of SUVmax were found with regard to tumour dimensions, histology (pure vs mixed, pleomorphic vs others), pathological stage and pattern of recurrence. P-stage, surgical radicality, vascular/lymphatic invasion but not SUVmax affected long-term survival in PSC.
KW - PET
KW - Pulmonary sarcomatoid carcinoma
KW - Rare lung tumours
KW - Survival
KW - SUV
UR - http://www.scopus.com/inward/record.url?scp=84974846052&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84974846052&partnerID=8YFLogxK
U2 - 10.1007/s00408-016-9904-1
DO - 10.1007/s00408-016-9904-1
M3 - Article
AN - SCOPUS:84974846052
SP - 1
EP - 5
JO - Lung
JF - Lung
SN - 0341-2040
ER -